COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,233 Articles (22,733 medRxiv, 8,500 bioRxiv)

Most recent first Previous |  Page 1644: Articles 16431-16440  | Next

Increasing concentration of COVID-19 by socioeconomic determinants and geography in Toronto, Canada: an observational study
Mishra, S., Ma, H., Moloney, G., Yiu, K. C., Darvin, D., Landsman, D., Kwong, J., Calzavara, A., Straus, S., Chan, A. K., Gournis, E., Rilkoff, H., Xia, Y., Katz, A., Williamson, T., Malikov, K., Kustra, R., Maheu-Giroux, M., Sander, B., Baral, S.
10.1101/2021.04.01.21254585 — Posted: 2021-04-06
Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests
Kanji, J. N., Bailey, A., Fenton, J., Ling, S. H., Rivera, R., Plitt, S., Sligl, W. I., Taylor, S. C., Turnbull, L., Tipples, G., Charlton, C. L.
10.1101/2021.03.30.21254604 — Posted: 2021-04-06
An Autoantigen-ome from HS-Sultan B-Lymphoblasts Offers a Molecular Map for Investigating Autoimmune Sequelae of COVID-19
Wang, J. Y., Zhang, W., Roehrl, V. B., Roehrl, M. W., Roehrl, M. H.
10.1101/2021.04.05.438500 — Posted: 2021-04-06
The Up state of the SARS-COV-2 Spike homotrimer favors an increased virulence for new variants
Correa Giron, C., Laaksonen, A., Barroso da Silva, F. L.
10.1101/2021.04.05.438465 — Posted: 2021-04-06 Discussion: Onsite
SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques
Garrado, C. G., Curtis, A. D., Dennis, M., Pathak, S. H., Gao, H., Montefiori, D., Tomai, M., Fox, C. B., Kozlowski, P. A., Scobey, T., Munt, J. E., Mallory, M. L., Saha, P. T., Hudgens, M. G., Lindesmith, L. C., Baric, R. S., Abiona, O. M., Corbett, K. S., Edwards, D., Carfi, A., Fouda, G., Van Rompay, K. K. A., De Paris, K., Permar, S. R.
10.1101/2021.04.05.438479 — Posted: 2021-04-06
A new SARS-CoV-2 lineage that shares mutations with known Variants of Concern is rejected by automated sequence repository quality control
Thornlow, B., Hinrichs, A. S., Jain, M., Dhillon, N., La, S., Kapp, J. D., Anigbogu, I., Cassatt-Johnstone, M., Mcbroome, J., Haeussler, M., Turakhia, Y., Chang, T., Olsen, H. E., Sanford, J., Stone, M., Vaske, O., Bjork, I., Akeson, M., Shapiro, B., Haussler, D., Kilpatrick, A. M., Corbett-Detig, R.
10.1101/2021.04.05.438352 — Posted: 2021-04-06 Discussion: Onsite | Offsite
On the many advantages of using the VariantExperiment class to store, exchange and analyze SARS-CoV-2 genomic data and associated metadata
Ambroise, J., Gatto, L., Hurel, J., Bearzatto, B., Gala, J.-L.
10.1101/2021.04.05.438328 — Posted: 2021-04-06
Rational Selection of PCR Primer/Probe Design Sites for SARS-CoV-2
Rana, D. R.
10.1101/2021.04.04.438420 — Posted: 2021-04-05
An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity
Motozono, C., Toyoda, M., Zahradnik, J., Ikeda, T., Saito, A., Tan, T. S., Ngare, I., Nasser, H., Kimura, I., Uriu, K., Kosugi, Y., Torii, S., Yonekawa, A., Shimono, N., Nagasaki, Y., Minami, R., Toya, T., Sekiya, N., Fukuhara, T., Matsuura, Y., Schreiber, G., The Genotype to Phenotype Japan (G2P-Japan) consortium, , Nakagawa, S., Ueno, T., Sato, K.
10.1101/2021.04.02.438288 — Posted: 2021-04-05
XAV-19, a novel swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike, efficiently neutralizes B.1.1.7 British and B.1.351 South-African variants.
Vanhove, B., Marot, S. S., Gaborit, B., Evanno, G., Malet, I., Ciron, C., Royer, P.-J., Lheriteau, E., Denie, S., Raffi, F., Duvaux, O., Marcelin, A.-G., Calvez, V.
10.1101/2021.04.02.437747 — Posted: 2021-04-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).